A series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells.
A series of preclinical experiments using patient-derived tumor xenografts (PDXs) and mouse models point to potential treatments for patients with a rapidly-progressing and resistant subgroup of tumor cells.